June 15, 2017 / 11:18 AM / a month ago

BRIEF-Seattle Genetics, Bristol-Myers Squibb highlight interim phase 1/2 data

1 Min Read

June 15 (Reuters) - Bristol-Myers Squibb Co:

* Seattle Genetics and Bristol-Myers Squibb highlight interim phase 1/2 data evaluating combination of adcetris® (brentuximab vedotin) and opdivo® (nivolumab) in relapsed hodgkin lymphoma at the international conference on malignant lymphoma

* Bristol-Myers Squibb Co - combination data show 85 percent objective response rate and 63 percent complete response rate

* Bristol-Myers Squibb-‍data support recently initiated pivotal phase 3 clinical trial evaluating adcetris & opdivo combination in relapsed hodgkin lymphoma​

* Bristol-Myers Squibb- ‍forty-five percent of patients had primary refractory disease, 55 percent progressed after responding to frontline therapy in study​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below